Puretech Health PLC 51.7% potential upside indicated by Liberum Capital

Broker Ratings

Puretech Health PLC with ticker (LON:PRTC) now has a potential upside of 51.7% according to Liberum Capital.

Liberum Capital set a target price of 580 GBX for the company, which when compared to the Puretech Health PLC share price of 280 GBX at opening today (09/12/2021) indicates a potential upside of 51.7%. Trading has ranged between 267 (52 week low) and 448 (52 week high) with an average of 135,549 shares exchanging hands daily. The market capitalisation at the time of writing is £815,814,571.

PureTech Health PLC is a clinical stage biotherapeutics company. The Company is engaged in discovering, developing and commercializing medicines for diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The Company’s wholly owned pipeline consists of six therapeutic candidates including LYT-100 (deupirfenidone), LYT-200, LYT-210, LYT-300 (oral allopregnanolone), LYT-500, and LYT-503/IMB-150. Its segments include Internal, Controlled Founded Entity, Non-Controlled Founded Entities, and Parent Company and Other. Its Internal segment is advancing wholly owned programs designed to harness immunological, fibrotic and lymphatic system mechanisms. These classes of immunomodulatory drugs are designed to treat serious diseases, including lung dysfunction, immuno-oncology, lymphatic, neurological and neuropsychological disorders.

You might also enjoy reading  PureTech Health Receives Approximately $100 Million from Sale of a Portion of Founded Entity Shares

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index